Rio Tinto Maintains Annual Guidance After 1Q Iron-Ore Shipments Fall 10%
By Stuart Condie
SYDNEY--Rio Tinto maintained its 2024 guidance after the Australian mining giant reported a 10% fall in first-quarter iron-ore shipments.
The world's second-biggest miner by market value on Wednesday said it shipped 78.0 million metric tons of iron ore from its mines in Australia's Pilbara region in the three months through March. That's a 10% decline compared to the immediately preceding December quarter, and down 5% on the same period a year ago.
Rio Tinto's iron-ore mining operations there are the biggest in the world, alongside a network of mines run by rival Vale SA in Brazil. Rio's first-quarter production was 77.9 million metric tons of iron ore, down 11% on-quarter.
Rio Tinto maintained its annual shipment guidance of 323 million-338 million metric tons. Production guidance for all materials and operating costs was also unchanged.
Write to Stuart Condie at stuart.condie@wsj.com
(END) Dow Jones Newswires
April 16, 2024 19:25 ET (23:25 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track